Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMET trial of luseogliflozin versus glimepiride with ranibizumab for diabetic macular edema in type 2 diabetes
jRCTs031180210Completed
- Sponsor
- Taisho Pharmaceutical
- Start
- Mar 2019
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial in diabetic macular edema (DME) and type 2 diabetes mellitus (T2DM) comparing Ranibizumab + luseogliflozin with Ranibizumab + glimepiride (2 arms). Primary endpoint: Intergroup difference in number of anti-VEGF intravitreal injections. Started Mar 2019; status: completed.
02
Drugs
ranibizumabluseogliflozinglimepiride
03
Conditions
diabetic macular edema (DME)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCTs031180210.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180210.